Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture (IRENE)

September 17, 2020 updated by: Laboratorios Ordesa

Clinical Trial to Assess the Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Elderly Patients With Spontaneous Hip Fracture

Multicenter, prospective, randomized, double-blind, interventional study with a nutritional supplement against placebo in a cohort of patients hospitalized for hip fracture.

Study Overview

Detailed Description

Hip fracture is a very prevalent pathology in the elderly population. It is estimated that 35-40% of people over 65 suffer a drop per year, and above 75 years this percentage is even higher, with hip fractures being one of the most serious consequences.With regard to malnutrition, the investigators know that aging carries an increased risk of suffering from decreased appetite and intake and changes in body composition. According to different series, the percentage of malnutrition in patients with hip fracture ranges from 13% to 60%. According to the hospital protocols in Spain in elderly people with spontaneous hip fracture, it is important to perform a nutritional screening during the first 24-48 hours of admission, to evaluate their nutritional status and apply a dietary treatment.

The IRENE study aims to determine whether phase angle and reactance, measured by electrical bioimpedance by vector analysis (BIVA) are related to functional recovery in patients with hip fracture.

Study Type

Interventional

Enrollment (Anticipated)

82

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Andalucía
      • Málaga, Andalucía, Spain, 29010
        • Hospital Clínico de Malaga
      • Sevilla, Andalucía, Spain, 41013
        • Hospital Virgen del Rocío

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients over 65 years old.
  • Patients admitted to hospital by spontaneous hip fracture and requiring surgery.
  • Patients who after hip intervention are included in rehabilitation protocols with outpatient rehabilitation plan.
  • Patients who agree to participate by signing informed consent or their regular caregivers grant consent.

Exclusion Criteria:

  • Patients who have a hip fracture from high-impact trauma or secondary to bone pathology (such as neoplasm).
  • Patients with concomitant diseases such as severe hepatic impairment, severe renal impairment, insulin-dependent diabetes melitus and decompensated diabetes mellitus.
  • Patients who require clinical stabilization before surgery beyond 72 hours.
  • Patients receiving emergency surgery.
  • Patients with previous prostheses.
  • Patients with pacemakers.
  • Patients who are not likely to complete the follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: FontActiv Superprotein/Hypercaloric Fiber
Full Nutritional Supplement
The product under study has a liquid presentation, in 200 ml bottles, ready to take
ACTIVE_COMPARATOR: Carbohydrates and C Vitamin
Nutritional Supplement
The control product will be prepared with equal presentation and taste as similar as possible tan study product

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare changes in nutritional status between groups based on phase angle
Time Frame: From baseline to month 4
Compare changes in nutritional status between patients taking nutritional supplement under study and control group based on phase angle measurement (morphological criterion)
From baseline to month 4
Compare changes in nutritional status between groups based on force measurement
Time Frame: From baseline to month 4
Compare changes in nutritional status between patients taking nutritional supplement under study and control group based on force measurement using hand-grip strength ( functional criteria).
From baseline to month 4

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To compare functional recovery
Time Frame: From baseline to month 4
Compare functional recovery using the Barthel Scale between patients taking nutritional supplement under study and placebo. It is scored on a scale ranging from 0 to 100, with 90 being the maximum score if the patient is in a wheelchair.
From baseline to month 4
To compare the morphological recovery by muscle ultrasound
Time Frame: From baseline to month 4
Compare the morphological recovery valued by muscle ultrasound between patients taking nutritional supplement under study and placebo. Ultrasound performed at baseline and month 4
From baseline to month 4
To compare changes in Mini Nutrition Assessment test for aged people
Time Frame: From baseline to month 4
Compare changes in the Mini Nutrition Assessment score between the two study groups. This is a validated test for aged people to assess the nutritional status. Good nutritional state: more than 17points. Bad nutritional state: less than 17 points.
From baseline to month 4
To compare the evolution of the Global Subjective Valuation questionnaire
Time Frame: From baseline to month 4
To compare the evolution of the Global Subjective Valuation between the two study groups. It is a method designed to estimate nutritional status through medical history and physical examination. Each of the sections is valued as mild, moderate or severe, being severe the worst nutritional condition.
From baseline to month 4
Compare changes between groups in the Charlson index
Time Frame: From baseline to month 4
Charlson index takes into account the number and severity of accompanying diseases to predict the risk of death. Each pathology that patient has, has a number. The higher the number, the worst prediction.
From baseline to month 4
Number of participants that have to be readmitted at the hospital.
Time Frame: From baseline to month 4
Compare the difference in hospital re-admissions between the two study groups.
From baseline to month 4
Number of participants that die during the study
Time Frame: From baseline to month 4
Compare the differences in mortality within four months of the start of the study between the two study groups
From baseline to month 4
Compare changes in the ratio RCP/Prealbumin index in the blood analysis
Time Frame: From baseline to month 4
Compare changes in the ratio RCP/Prealbumin index between the two study groups.
From baseline to month 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jose Manuel Garcia Almeida, Hospital Clínico de Malaga

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

September 1, 2020

Primary Completion (ANTICIPATED)

May 1, 2021

Study Completion (ANTICIPATED)

May 1, 2021

Study Registration Dates

First Submitted

November 25, 2019

First Submitted That Met QC Criteria

December 2, 2019

First Posted (ACTUAL)

December 3, 2019

Study Record Updates

Last Update Posted (ACTUAL)

September 18, 2020

Last Update Submitted That Met QC Criteria

September 17, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malnutrition

Subscribe